Krystal Biotech, Inc.
KRYS
Positions held
Your positionsKRYS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Krystal Biotech operates in the rapidly growing biotechnology sector, focusing on innovative gene therapies that address unmet medical needs, positioning itself for significant market opportunities.
- The company's revenue grew by 2% in the last quarter, reaching $119 million, indicating strong demand for its products.
- Krystal Biotech reported a gross margin of 94.6% in the latest quarter, demonstrating its ability to maintain high profitability.
- Despite its potential, Krystal Biotech has a 'Strong Sell' signal with a score of -26.00, indicating significant bearish sentiment among analysts.
- The company's operating margin has shown volatility, with a negative operating margin of -191.56% reported in 2023, raising concerns about its financial stability.
- The stock's RSI is at 45, suggesting it is nearing oversold conditions, which could lead to further downward pressure.
Fundamentals
| Market cap | $9.69B | Enterprise value | $8.85B | Trailing P/E | 41.02 | Forward P/E | 35.33 |
| PEG | — | Price / book | 7.13 | Beta | 0.50 | Dividend yield | 0.00% |
| Revenue growth | 24.1% | Earnings growth | 38.8% | Gross margin | 94.6% | Operating margin | 49.0% |
| Profit margin | 54.8% | ROE | 20.1% | ROA | 9.4% | Debt / equity | 0.01 |
| Current ratio | 8.32 | Free cash flow | $151.74M | Analyst recommendation | strong_buy | Mean target | $392.11 |
| 52w high | $382.54 | 52w low | $179.19 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $119M | $116M | $107M | $97.8M | $96.0M | — |
| Op margin | 49.0% | 46.1% | 41.3% | 42.3% | 41.0% | — |
| Net income | $54.8M | $55.9M | $51.4M | $79.4M | $38.3M | — |
| Gross margin | 94.6% | 94.6% | 93.8% | 95.6% | 92.5% | — |
| Gross profit | $113M | $110M | $101M | $93.5M | $88.9M | — |
| Operating income | $58.4M | $53.7M | $44.3M | $41.4M | $39.4M | — |
- Revenue +2% vs prior quarter ($119M vs $116M).
- Gross margin 94.6% (was 94.6% prior quarter).
- Operating margin expanded to 49%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $389M | $291M | $50.7M | $0.0M | — |
| Op margin | 41.5% | 35.5% | -191.6% | — | — |
| Net income | $205M | $89.2M | $10.9M | -$140M | — |
| Gross margin | 94.1% | 93.1% | 93.9% | — | — |
| Gross profit | $366M | $270M | $47.6M | $0.0M | — |
| Operating income | $161M | $103M | -$97.1M | -$120M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders
2026-10-08 · Why Krystal Biotech (KRYS) Is Drawing Fresh Attention
2026-10-08 · Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x Run
2026-10-06 · Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?
2026-09-21 · BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating
2026-09-08 · Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing
2026-09-08 · Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing
2026-09-03 · Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
2026-09-03 · Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
2026-09-03 · Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
2026-09-02 · Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
2026-08-17 · Krystal Biotech Insider Sold Shares Worth $8,227,953, According to a Recent SEC Filing
Price (daily)
Full chart · RSI · MACD · patterns